Genetic engineering for human bypass vein grafts
Reference30 articles.
1. Chang MW, Barr E, Seltzer J, Jiang YQ, Nabel GJ, Nabel EG, Parmacek MS, Leiden JM (1995) Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science 267: 518–522
2. Clowes AW, Reidy MA (1991) Prevention of stenosis after vascular reconstruction: Pharmocologic control of intimal hyperplasia - A review. J Vase Surg 13: 885–891
3. Cox JL, Chaisson DA, Gotleib AI (1991) Stranger in a strange land: The pathogenesis of saphenous vein graft stenosis. Prog Cardiovasc Dis 34: 45–68
4. Degregori J, Kowalik T, Nevins Jr (1995) Cellular targets for activation by the E2fl transcription factor include DNA synthesis- and Gl/S-regulatory genes. Mol Cell Biol 15: 4215–4224
5. Dev V, Parikh A, Ren M, Goldenberg T, Fishbein MC, Eigler N, Rossi J, Litvack F (1995) Ribozymes to cell division cycle (Cdc-2) kinase and proliferating cell nuclear antigen (Pcna) prevent intimal hyperplasia in rat carotide artery (abstract). Circ (Suppl I) 92:1–634